Lupus

The next therapeutic innovation in complement biology therapies for rheumatic diseases may involve inhibiting the alternative complement pathway, according to a speaker at the Biologic Therapies Summit.

In patients with systemic lupus erythematous, CAR T-cell therapy appears to be a feasible and effective method of achieving durable remission, according to a speaker at the Biologic Therapies Summit.

DESTIN, Fla. — Dermatomyositis and tinea are just two of many dermatologic complications that may resemble rheumatologic conditions, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

DESTIN, Fla. — Hydroxychloroquine remains one of the most important drugs in lupus management and should be used as background therapy in nearly all cases, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

The FDA has granted fast-track designation to CABA-201, a CD19-CAR T cell investigational therapy, for the treatment of systemic lupus erythematous and lupus nephritis, according to a press release from the manufacturer.

Patients with pulmonary arterial hypertension associated with connective tissue disease demonstrate a “poor” 10-year rate of 59.9%, according to data published in Rheumatology.

Baricitinib met the primary endpoint in one phase 3 study of patients with systemic lupus erythematosus, but failed to meet the same endpoint in a second trial aiming to repeat the results, according to data published in The Lancet.

The Lupus Research Alliance and the FDA have announced a public-private partnership to increase collaboration and further the advancement of personalized therapies for lupus.

The real-world use of Pneumocystis jirovecii pneumonia prophylaxis in patients with systemic lupus erythematous is “much lower” than prior survey-based studies suggest, according to data published in Seminars in Arthritis and Rheumatism.